Management of febrile neutropenia - A German prospective Hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer

Onkologie

Volumn 34, Issue 5, 2011, Pages 241-246

  Ihbe Heffinger, Angela ^a,b   Paessens, Bernadette J ^a   Von Schilling, Christoph ^a,c   Shlaen, Margarita ^d   Gottschalk, Nina ^b   Berger, Karin ^e   Bernard, Rudolf ^a   Kiechle, Marion ^b   Peschel, Christian ^a   Jacobs, Volker R ^b,f  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Frauenklinik ^*  (Germany)

^c Klinikum Freising   (Germany)

^d IQVIA   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adverse effects; Combined antineoplastic treatment protocols; Costs and cost analysis; Health resources; Leukopenia; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; GERMANY; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITAL COST; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LEUKOPENIA; LONGITUDINAL STUDY; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; FEVER; GERMANY; HEALTH CARE COSTS; HUMANS; INCIDENCE; LUNG NEOPLASMS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 79957486287     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000327711     Document Type: Article

References (21)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
2. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
3. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW: Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82(suppl 2):S105-117. (Pubitemid 37265297)
4. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531. (Pubitemid 46594022)
5. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311. (Pubitemid 41185151)
6. Liou S: Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007;27:381-396. (Pubitemid 46873100)
7. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G: Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-460. (Pubitemid 351325664)
8. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266. (Pubitemid 43673249)
9. Bennett CL, Calhoun EA: Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-483. (Pubitemid 46698725)
10. Mayordomo JI, Lopez A, Vinolas N, Castellanos J, Pernas S, Domingo Alonso J, Frau A, Layola M, Antonio Gasquet J, Sanchez J: Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009;25:2533-2542.
11. Paessens BJ, von Schilling C, Ehlken B, Shlaen M, Berger K, Bernard R, Peschel C, Ihbe-Heffinger A: Resource use and costs associated with routine management of chemotherapy associated toxicity in German hospitals. Ann Oncol 2008;19(suppl 8):viii272 (886O).
12. The Uppsala Monitoring Centre: The use of the WHO-UMC system for standardised case causality assessment; www.who-umc.org/graphics/4409.pdf.
13. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205. (Pubitemid 46638957)
14. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thodtmann J, Lordick F: The impact of delayed chemotherapyinduced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-536. (Pubitemid 38444561)
15. Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, Biesma B, Gorlia T, Crott R, Giaccone G, Debruyne C, Manegold C: Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol 2003; 14:248-257.
16. Herold M, Hieke K: Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econ 2002;3:166-172. (Pubitemid 36401999)
17. Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC: Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290-296.
18. Braun M, Jacobs VR, Wagenpfeil S, Sattler D, Harbeck N, Nitz U, Bernard R, Kuhn W, Ihbe- Heffinger A: Cost analysis comparing an anthracycline/ docetaxel regimen to CMF in patients with early stage breast cancer. Onkologie 2009;32:473-481.
19. Paessens BJ, von Schilling C, Berger K, Shlaen M, Müller-Thomas C, Bernard R, Peschel C, Ihbe- Heffinger A: Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and nsclc patients. Ann Oncol 2011;DOI 10.1093/annonc/mdq759;Epub ahead of print.
20. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J: The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051. (Pubitemid 30644129)
21. Lalami Y, Paesmans M, Muanza F, Barette M, Plehiers B, Dubreucq L, Georgala A, Klastersky J: Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 2006;17:507-514. (Pubitemid 43329591)